Shares of ImmuPharma plc (LON:IMM – Get Free Report) traded down 31.4% during mid-day trading on Tuesday . The company traded as low as GBX 6.70 and last traded at GBX 6.70. 27,337,178 shares traded hands during mid-day trading, an increase of 242% from the average session volume of 7,982,150 shares. The stock had previously closed at GBX 9.76.
ImmuPharma Price Performance
The business’s 50 day simple moving average is GBX 10.96 and its 200-day simple moving average is GBX 5.84. The stock has a market capitalization of £34.63 million, a P/E ratio of -7.74 and a beta of 1.53.
ImmuPharma Company Profile
ImmuPharma PLC (LSE AIM: IMM) is a specialty biopharmaceutical company that discovers and develops peptide-based therapeutics. The Company’s portfolio includes novel peptide therapeutics for autoimmune diseases and anti-infectives. The lead program, P140 (Lupuzor™), is a first-in class autophagy immunomodulator for the treatment of Lupus and preclinical analysis suggest therapeutic activity for many other autoimmune diseases that share the same autophagy mechanism of action.
Read More
- Five stocks we like better than ImmuPharma
- What Are Treasury Bonds?
- D-Wave: Time to Buy the Dip? Or is the Fall Just Starting?
- How to Calculate Return on Investment (ROI)
- Hims, Block, and NRG Just Launched Huge Stock Buybacks
- How to Use High Beta Stocks to Maximize Your Investing Profits
- Retail Earnings Roundup: Walmart Scores, Target Slumps in Q3
Receive News & Ratings for ImmuPharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for ImmuPharma and related companies with MarketBeat.com's FREE daily email newsletter.
